Business
BioSpectrum Asia
India develops drug delivery system to revolutionise treatment of Rheumatoid Arthritis
Researchers from Institute of Nano Science and Technology (INST) Mohali, an autonomous institution of the Department of Science and Technology (DST), Government of India, have developed an innovative “self-actuating” drug delivery system that could revolutionise the treatment of rheumatoid arthritis (RA) by targeting inflammation directly within the joints so that therapeutic agents are released only when needed.
1 min |
March 2025
BioSpectrum Asia
NephroPlus increases footprint in the Philippines with acquisition of 7 dialysis centres
NephroPlus, Asia’s largest dialysis care network, has acquired seven new dialysis clinics in the Philippines, enhancing its position as a leading dialysis provider in the country.
1 min |
March 2025
BioSpectrum Asia
India and Indonesia ink MoU in the field of traditional medicine
The Prime Minister of India, Narendra Modi and the President of Indonesia, Prabowo Subianto witnessed the Exchange of Memorandum of Understanding (MoU) between India and Indonesia.
1 min |
March 2025
BioSpectrum Asia
BioAsia 2025 announces Genome Valley Excellence Award to Singapore's Prof. Patrick Tan
BioAsia, Asia's largest annual global biotechnology and life sciences forum organised by the Government of Telangana, has announced that the prestigious Genome Valley Excellence Award has been conferred upon Prof. Patrick Tan, Executive Director of PRECISE (Precision Health Research, Singapore), National University of Singapore, for his outstanding contributions to precision medicine, cancer genomics, and population health research.
1 min |
March 2025
BioSpectrum Asia
Syngene CEO Jonathan Hunt steps down, Peter Bains takes over
Syngene International Limited has announced that Jonathan Hunt has stepped down from his role as Managing Director (MD) & Chief Executive Officer (CEO) as well as from the Board of Directors to pursue other opportunities in due course.
1 min |
March 2025
BioSpectrum Asia
Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO
Daiichi Sankyo Company has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, PhD as Chief Executive Officer (CEO), effective April 1, 2025. Dr Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Okuzawa will transition to Representative Director, President and CEO.
1 min |
March 2025
BioSpectrum Asia
Chugai and GSK sign collaboration agreement for anti-dengue virus antibody AID351
Japan's Chugai Pharmaceutical Co. has signed a collaboration agreement with GSK's Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody.
1 min |
March 2025
BioSpectrum Asia
Bain Capital to acquire Mitsubishi Tanabe Pharma for $3.3 B
Bain Capital, a leading global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out transaction from Mitsubishi Chemical Group Corporation.
1 min |
March 2025
BioSpectrum Asia
Julie Kim to succeed Christophe Weber as CEO of Takeda in June 2026
Japan headquartered pharmaceutical firm Takeda has announced that its Board of Directors have made the decision unanimously to appoint Julie Kim, currently president of Takeda’s US Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Weber retires from the company in June 2026.
1 min |
March 2025
BioSpectrum Asia
Vaxxas advances $4.8 M programme for needle-free thermostable mRNA vaccines
Vaxxas, an Australia-based clinical-stage biotechnology company commercialising a novel high-density microarray patch (HD-MAP) vaccination platform, has announced that Norwaybased Coalition for Epidemic Preparedness Innovations (CEPI) has approved the progression of a $4.8 million (AU$7.2 million) programme to develop heat-stable, dried-formulation mRNA vaccines delivered using Vaxxas’ needle-free high-density microarray patch (HD-MAP).
1 min |
March 2025
BioSpectrum Asia
PHC partners with CCRM in Canada to develop primary T-cell expansion culture processes
Japan-based PHC Corporation has signed a Master Collaboration Agreement with CCRM (based in Canada) to work together on the development of primary T-cell expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products.
1 min |
March 2025
BioSpectrum Asia
Korea announces Top 10 Promising Biotechnologies of 2025
The Ministry of Science and ICT and the Korea Research Institute of Bioscience and Biotechnology have announced the \"Top 10 Promising Biotechnologies of 2025\", presenting a vision for the future of life sciences.
1 min |
March 2025
BioSpectrum Asia
Singapore to establish Communicable Diseases Agency
The Ministry of Health (MOH) in Singapore will establish a new Statutory Board, the Communicable Diseases Agency (CDA), on April 1, 2025.
1 min |
March 2025
BioSpectrum Asia
Hong Kong develops world's smallest multifunctional biomedical robot
Researchers from the School of Engineering of the Hong Kong University of Science and Technology have successfully developed the world's smallest multifunctional biomedical robot, which is 60 per cent smaller than current models.
1 min |
March 2025
BioSpectrum Asia
American University in Dubai partners with University of Pennsylvania to establish new School of Medicine
The American University in Dubai (AUD) has completed a Memorandum of Understanding (MoU) to partner with the University of Pennsylvania’s Perelman School of Medicine (Penn Medicine) in establishing the AUD School of Medicine in Dubai.
1 min |
March 2025
BioSpectrum Asia
AdvanCell partners with Lilly to develop new targeted alpha therapies for cancer treatment in Australia
AdvanCell, a radiopharmaceutical company, has announced the expansion of the scope and scale of its strategic collaboration with Eli Lilly and Company for the research and development of innovative treatments for various cancers.
1 min |
March 2025
BioSpectrum Asia
Australia offers new treatment hope for childhood cancers
University of Queensland (UQ) research using \"natural killer\" cells may lead to the first new treatment for a devastating childhood cancer in 40 years.
1 min |
March 2025
BioSpectrum Asia
XDENT LAB expands largest removable denture factory in Vietnam
XDENT LAB, one of the leading providers in the field of Removable Denture manufacturing in Vietnam, has officially announced the expansion of its production facility, making it the largest in the country.
1 min |
March 2025
BioSpectrum Asia
UK launches world-leading AI trial to tackle breast cancer
The Department of Health and Social Care in the UK government has announced that nearly 700,000 women across the country will take part in a world-leading trial to test how cutting-edge artificial intelligence (AI) tools can be used to catch breast cancer cases earlier.
1 min |
March 2025
BioSpectrum Asia
WHO certifies Georgia malaria-free
Following a nearly century-long effort, Georgia has been certified malaria-free by the World Health Organization (WHO) on January 23.
1 min |
March 2025
BioSpectrum Asia
New Zealand announces Public Health Surveillance Strategy
New Zealand’s first Public Health Surveillance Strategy has been announced by the Ministry of Health (MoH) on how to gather and coordinate public health information to better protect New Zealanders against threats to their health and wellbeing.
1 min |
March 2025
BioSpectrum Asia
Empowering Women in STEM: Viet Nam's Journey Towards Innovation and Equality
2025 marks the 10th anniversary of the International Day of Women and Girls in Science (IDWGS) (observed on February 11) and the 30th anniversary of the Beijing Declaration and Platform for Action, two significant milestones in the global effort to promote gender equality and women's empowerment. Recognising the importance of gender inclusivity, Viet Nam has taken major policy steps to empower female researchers and entrepreneurs. By investing in education, policy reforms, and celebrating the achievements of women scientists, the country is setting a global example for inclusive development.
4 min |
March 2025
BioSpectrum Asia
ADCS on the rise: A Trojan Horse Race for Patients
Antibody-Drug Conjugates (ADCs) have emerged as a major therapeutic approach creating new opportunities for a range of cancer treatments. The recent scientific and clinical progress in the ADC field underscores its importance for ongoing research.
4 min |
March 2025
BioSpectrum Asia
A Wake-Up Call for International Women's Day
International Women's Day (IWD) (celebrated on March 8) has been around for over a hundred years, as have many of the issues still impacting women's advancement. Since 1911, IWD belongs to all who care about women's equality. At the current rate of progress, it will take until 2158, which is roughly five generations from now, to reach full gender parity, according to data from the World Economic Forum. Focusing on the need to Accelerate Action (theme for IWD 2025) emphasizes the importance of taking swift and decisive steps to achieve gender equality. Talking about the status of women in Australian life sciences space, the article calls for an action for better health, great businesses and a stronger economy.
3 min |
March 2025
BioSpectrum Asia
Collaboration vs.Competition: Patent Cliffs
The biosimilar business is growing increasingly fragmented among smaller firms, even as larger corporations are merging. Biosimilars are being developed by more than 40 smaller companies, many of which have no prior experience in the field. Long-term viability and supply reliability are threatened by this fragmentation.
3 min |
March 2025
BioSpectrum Asia
"Biotech sector in Taiwan moves fast, making it easier to pivot and innovate"
Caliway Biopharmaceuticals has recently announced the completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919). The round raised approximately $206 million (NT$6.4 billion), marking it the largest IPO in Taiwan's biotech industry history and valuing the company at nearly $3 billion. The company is poised for a transformation in 2025, advancing its groundbreaking clinical programmes and strengthening its global market presence. Following its recent record-breaking IPO, BioSpectrum Asia took an opportunity to speak with Vivian Ling, Chief Executive Officer & Chief R&D Officer, Caliway Biopharmaceuticals to explore their innovative contributions in biopharmaceuticals. Edited excerpts:
4 min |
March 2025
BioSpectrum Asia
"Personalised medicine is now a reality, not just an aspiration"
Terumo Blood and Cell Technologies, (a subsidiary of Terumo Corporation, Japan) is at the forefront of advancing blood- and cell-based therapies. In an interview with BioSpectrum Asia, Antoinette Gawin, President and CEO,Terumo Blood and Cell Technologies outlines the company’s current strategy, key projects, the importance of the APAC region, and her perspective on evolving trends in the industry.
4 min |
March 2025
BioSpectrum Asia
Rise of ADCs: Expanding Applications and the Road to Commercialisation
The development of antibody-drug conjugates (ADCs) has advanced significantly in the biopharmaceutical sector; in the last five years, eight of the 14 ADCs that are currently approved have obtained regulatory approval. The quantity of pre-clinical to commercial ADC compounds in the innovative modality pipeline increased by more than 25 per cent year over year, according to a market trend. ADCs have the potential to transform targeted medicine and give patients everywhere new hope with further development and wise funding.
4 min |
March 2025
BioSpectrum Asia
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
10 min |
March 2025
BioSpectrum Asia
How Degrader-Antibody Conjugates Are Transforming Precision Medicine for Oncology & Beyond
Targeted cancer therapy has advanced significantly with the creation of Degrader-antibody conjugates (DACs). The shortcomings of conventional ADCs are addressed by DACs, which combine the specificity of antibodies with the special capacity of protein degraders to eradicate important oncogenic drivers.
2 min |